Published on 5 Nov 2023 on Simply Wall St. via Yahoo Finance
Prelude Therapeutics Insiders Are Down US$149k But Regain Some Losses
Insiders who bought US$263.0k worth of Prelude Therapeutics Incorporated (NASDAQ:PRLD) stock in the last year have seen some of their losses recouped as the stock gained 25% last week. The purchase, however, has proven to be a pricey bet, with losses currently totalling US$149k.
Although we don't think shareholders should simply follow insider transactions, logic dictates you should pay some attention to whether insiders are buying or selling shares.
See our latest analysis for Prelude Therapeutics